|
21 Mar 2007 |
Dharma Therapeutic Shows IDDS is Effective in Reducing Pain Associated with Insertion of an Intravenous Catheter in their Phase 2 Clinical Trial
|
|
21 Mar 2007 |
Resverlogix Advances RVX-208 IND Program to Parallel Human Microdosing
|
|
21 Mar 2007 |
Cannasat Therapeutics and IntelGenx Enter Into Agreement to Develop Cannabinoid-Based Products for the Treatment of Mood Disorders Such as Anxiety and Depression
|
|
21 Mar 2007 |
Keppra(R) Approved for US Epilepsy Patients with One of the Most Debilitating Seizure Types
|
|
21 Mar 2007 |
Takeda Submits a European Marketing Authorization
|
|
21 Mar 2007 |
Astellas Receives an FDA Action Letter for Prograf sNDA
|
|
21 Mar 2007 |
Jerini Announces Establishment of Wholly-Owned US Subsidiary Aimed at Developing Treatments for Eye Diseases
|
|
21 Mar 2007 |
Myriad Genetics Completes Enrollment in Second Phase 3 Clinical Trial of Flurizan(TM) in Alzheimer's Disease
|
|
21 Mar 2007 |
Cell Therapeutics Inc. (CTI) Files for Special Protocol Assessment (SPA) for XYOTAX(TM) PGT307 Lung Cancer Trial in Women
|
|
21 Mar 2007 |
Avexa Limited (AVX.AX) Reports Positive Phase IIb Results
|
|
21 Mar 2007 |
Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
|
|
21 Mar 2007 |
Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
|
|
20 Mar 2007 |
Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet Primary Endpoint
|
|
20 Mar 2007 |
ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial
|
|
20 Mar 2007 |
Neuropharma presents advances in the development of NP-61 at the Alzheimer's and Parkinson's Diseases International Conference
|
|
20 Mar 2007 |
Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
|
|
20 Mar 2007 |
Akesis Pharmaceuticals Obtains Exclusive License for Proprietary Clinical Stage Diabetes Therapy from the University of British Columbia
|
|
20 Mar 2007 |
New Phase IV Clinical Study Indicates LidoSite(R) Provides Rheumatology Patients Superior Pain Relief
|
|
20 Mar 2007 |
In new study, Duloxetine reduced non-specific pain and emotional symptoms associated with depression
|
|
20 Mar 2007 |
Medivation Announces Presentation of Full Top-Line Data From Dimebon(TM) Six-Month Trial at Major International Alzheimer's Disease Conference
|
|
20 Mar 2007 |
Corcept Therapeutics Inc. Announces Phase 3 Study Evaluating CORLUX(R) for Psychotic Major Depression Misses Primary Endpoint
|
|
20 Mar 2007 |
Advanced Magnetics Completes Enrollment in Final Planned Phase III Study of Ferumoxytol as an IV Iron Replacement Therapeutic
|
|
19 Mar 2007 |
SEROQUEL(R) Sustained Release Schizophrenia Data presented at ECP Congress in Madrid
|
|
17 Mar 2007 |
Abeille Licenses AB-1001 to SymBio Pharmaceuticals for Commercialization in Japan and Pacific Rim Countries
|
|
17 Mar 2007 |
Amicus Therapeutics, Inc. Completes Phase 2 Enrollment of Amigal(TM) for Fabry Disease
|
